You are here: Home › News › News archive › Solvay Pharmaceuticals acquires Innogenetics

Solvay Pharmaceuticals acquires Innogenetics

9 September 2008-Solvay Pharmaceuticals S.A. succeeded to acquire Innogenetics N.V., a Belgian-based biotechnological company.

Solvay Group now holds 84.3% of the Innogenetics shares, including the participation of 9.68 % which Solvay held prior to the offer.

Document Actions

Send this

Navigation

Column

Penny-wise!

Synaps bij column Arjen Brussaard, foto CNCR.nl

By Arjen Brussaard

Recently the topsector plan Life Sciences & Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.
More...

Submit a news item!

News

Partners in the Cluster can submit news items to be circulated widely via the homepage of the Amsterdam BioMed Cluster.

Or add us to your mailing list for press releases: info[at]amsterdambiomed.nl

Personal tools

Solvay Pharmaceuticals acquires Innogenetics

Document Actions

Penny-wise!

Find your life sciences partner in the Amsterdam BioMed Cluster